title: Emergence of antibiotic resistance and prudent use of antibiotic therapy in nosocomially acquired urinary tract infections.
abstract: Nosocomially acquired urinary tract infections (NAUTI) are common. The reported rates, however, depend very much on the definitions used and the number of investigations requested. In a prospective study on a surgical intensive care unit and adhering closely to the CDC criteria, NAUTI was diagnosed in about 17% of the patients. The urinary catheter associated UTI rate per 1000 catheter days was 14.5 much higher than otherwise reported. Whereas the rates of symptomatic NAUTI and other nosocomially acquired infections were similar, the main difference was found for asymptomatic UTI which depends very much on the effort to search for it systematically. In a prospective study on a urological ward it could be demonstrated that cross-transmission probably plays a much greater role than so far suggested. Continuous surveillance of the bacterial spectrum and resistance is necessary not only on a global but also on a local level. Selection of an appropriate agent for empirical antibacterial therapy can be better tailored if not only the total bacterial spectrum is considered but if all information already available during the identification process is used, such as Gram stain and other simple and rapid tests for stratification of the pathogens. Since in NAUTI usually some kind of biofilm infection is involved, the fluoroquinolones can be considered agents of choice. Only those substances with high antibacterial activity, good bioavailability and those that are mainly excreted by the kidneys should be chosen and they have to be administered at sufficiently high doses.
authors.affiliation: Urologic Clinic, Hospital St. Elisabeth, St. Elisabeth Strasse 23, D-94315 Straubing, Germany. wagenlehner@aol.com
authors.forename: F M E
authors.initials: FM
authors.lastname: Wagenlehner
authors.forename: K G
authors.initials: KG
authors.lastname: Naber
mesh_terms: D000900:Anti-Bacterial Agents / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use*; D001419:Bacteria / Q000187:drug effects; D003428:Cross Infection / Q000188:drug therapy*; D003937:Diagnosis, Differential; D024881:Drug Resistance, Bacterial; D006801:Humans; D014552:Urinary Tract Infections / Q000145:classification / Q000175:diagnosis / Q000188:drug therapy*
chemical_list: D000900:Anti-Bacterial Agents